Fig. 8: ROCK2 transformed ZEB1 to activator via YAP1.
A ChIP assay for ATM promoter with YAP1-siRNA, and expression of ATM protein was determined with YAP1-siRNA. B IP assay for YAP1 and ZEB1. C ROCK2 regulated YAP1 expression. D YAP1 expression in 693 glioma patients as determined by CGGA online tools. E Co-expression analysis of YAP1 and ROCK2 mRNA level in subset of recurrent gliomas. F Luciferase activities were determined after transfection with YAP-1 shRNA in U87R, U87R-ROCK2OE, U251R and U251R-ROCK2-OE cells. Luciferase were detected. G ChIP assay of ZEB1 on ATM promotor was determined with transfection of YAP1-shRNA in U87R, U87R-ROCK2OE, U251R and U251R-ROCK2OE cells. H YAP1, ZEB1 and ATM levels in YAP1-KD cells were determined by WB. I, J ATM gene expression was detected by Q-PCR after transfection of YAP-shRNA or YAP-overexpression plasmid in U87R, U87R-ROCK2OE, U251R and U251R-ROCK2OE cells. K, L ROCK2, YAP1, ZEB1 and ATM expressions were determined by WB after transfection of YAP-shRNA or YAP-overexpression plasmid in U87R, U87R-ROCK2OE, U251R and U251R-ROCK2OE cells. M Mechanisms through which ROCK2 mediates TMZ-resistance in MGMTlow glioma. Data are expressed as mean ± SD of three independent experiments. p values determined by ANOVA or two-tailed unpaired t-test. Statistical differences compared with the controls are given as *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
